New antibiotics for community-acquired pneumonia

Marin H. Kollef, Kevin D. Betthauser

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Purpose of reviewThis review provides the rationale for the development of new antibiotics to treat community-acquired pneumonia (CAP). It also provides an overview of the new antibiotics targeting CAP that have recently received approval by the regulatory agencies, and those antibiotics that are in the development pipeline.Recent findingsCAP is one of the most common reasons for hospitalization and carries a significant morbidity and risk of mortality. Increasing antibiotic resistance amongst the common bacterial pathogens associated with CAP, especially staphylococci and Streptococcus pneumoniae, has made the empiric treatment of this infection increasingly problematic. Moreover, failure of initial empiric therapy to cover the causative agents associated with CAP can be associated with worse clinical outcomes. There have been several antibiotics newly approved or in development for the treatment of CAP. These agents include delafloxacin, omadacycline, lefamulin, solithromycin, nemonoxacin, and ceftaroline. Their major advantages include activity against methicillin-resistant Staphylococcus aureus and macrolide-resistant Strep. pneumoniae.SummaryCAP continues to be an important infection because of its impact on patient outcomes especially in the elderly and immunocompromised hosts. The availability of new antibiotics offers an opportunity for enhanced empiric treatment of the antibiotic-resistant bacterial pathogens associated with CAP.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalCurrent Opinion in Infectious Diseases
Issue number2
StatePublished - Apr 1 2019


  • antibiotics
  • community-acquired pneumonia
  • outcomes
  • resistance


Dive into the research topics of 'New antibiotics for community-acquired pneumonia'. Together they form a unique fingerprint.

Cite this